OSCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Oscar Health Inc (OSCR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown improvements in revenue and net income, the technical indicators are mixed, and there are no strong proprietary trading signals or recent positive news catalysts to support an immediate buy decision. The stock's pre-market decline and bearish moving averages suggest caution, and the options sentiment is neutral. Analysts' ratings are improving, but the stock's near-term price trend is uncertain. Holding off for more clarity or stronger signals is recommended.
The MACD is positive and expanding, indicating potential bullish momentum. However, the RSI is neutral at 59.644, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are at 13.18 (pivot), 14.27 (R1), and 12.089 (S1). The stock's pre-market price is 13.55, down 0.81%, which is below the pivot level, suggesting potential downside risk.
Analysts' ratings have improved recently, with upgrades from Raymond James, UBS, and Barclays citing attractive valuation and margin recovery. Revenue growth of 17.30% YoY and a significant improvement in net income (-129.64% YoY) are positive indicators for long-term potential.
The stock's bearish moving averages, pre-market price decline, and lack of recent news or significant trading trends from hedge funds or insiders are negative signals. Additionally, the company's gross margin remains at 0, and its EPS is still negative (-1.24).
In Q4 2025, Oscar Health reported revenue growth of 17.30% YoY to $2.81 billion. Net income improved significantly by 129.64% YoY to -$352.61 million, and EPS increased by 100% YoY to -1.24. However, gross margin remains at 0, indicating ongoing profitability challenges.
Recent analyst ratings are mixed but improving. Raymond James upgraded the stock to Outperform with an $18 price target, citing attractive valuation and margin recovery. UBS lowered its price target to $15 but maintained a Neutral rating. Barclays upgraded the stock to Equal Weight with an $18 price target, highlighting potential margin expansion and undervaluation. Jefferies remains bearish with an Underperform rating and a $12 price target, citing risks related to subsidies and enrollment trends.
